1. Introduction {#sec0005}
===============

Since the first confirmed case in Wuhan in 2019 \[[@bib0005]\], the Coronavirus Disease 2019 (COVID-19) has rapidly spread on a global scale. More than three million confirmed infections have been reported according to the World Health Organisation (WHO) \[[@bib0010]\]. To date, there are no specific or effective therapies approved for treatment of this fatal disease \[[@bib0015]\]. In many countries, public health services have been overwhelmed by the rapid rise in new COVID-19 cases. This has resulted in a high severity and mortality \[[@bib0020],[@bib0025]\]. Therefore, it is important that clinicians identify the risk factors or acquiring COVID-19 infection, pay attention to the risk factors associated with critical disease and death, and take appropriate interventions. By focusing on these aspects, infections may be prevented, the efficacy of treatment may be enhanced, and the risk of death may be reduced.

The latest systematic review investigating COVID-10 patients reported that hypertension and cardiovascular disease (CVD) were associated with a higher risk of severity and mortality in patients infected with COVID-19 \[[@bib0030]\]. However, patients with these comorbidities are likely to be treated with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), which could upregulate the expression of ACE2 receptor in animal studies \[[@bib0035],[@bib0040]\]. Since ACE2 is the functional receptor for coronavirus entry into cells \[[@bib0045]\], there is concern regarding an increased risk of COVID-19 infection among those who use ACEI/ARB treatment \[[@bib0050]\]. Conversely, there is evidence that exogenous ACE2 supplementation can reduce inflammation and increase oxygenation in animal models of acute respiratory distress syndrome (ARDS) \[[@bib0055]\]. Epidemiological studies have also shown that ACEI/ARB use may reduce the risk of pneumonia in the general population \[[@bib0060],[@bib0065]\]. These observations raise the question as to whether ACEI/ARB exposure is associated with risk or progression of COVID-19. To provide more accurate evidence, we conducted a meta-analysis. Thus, the aims of this work were as follows: (1) to determine whether ACEI/ARB use is associated with an increase in likelihood of viral infectivity; (2) to investigate whether there are differences in severity and mortality between ACRI/ARB users and non- ACRI/ARB users; (3) to evaluate, in particular, whether ACEI/ARB exposure was associated with a lower risk of mortality when compared to non-ACEI/ARB antihypertensive drug exposure. Our findings provide vital guidance for current clinical work on the prevention and treatment of COVID-19 infection.

2. Materials and methods {#sec0010}
========================

2.1. Literature search {#sec0015}
----------------------

To ensure high-quality evidence, we followed the Preferred Reporting Items of Systematic Reviews and Meta-analysis (PRISMA) statement. A comprehensive search of the PubMed, Embase, and Cochrane Library databases was performed to identify all relevant articles published between Jan 1, 2020 and May 9, 2020. The search terms were as follows: 'Corona Virus Disease-2019 OR 2019 novel coronavirus OR SARS-CoV-2 OR COVID-19 OR 2019-nCoV' AND 'antihypertensive agent OR hypertension OR angiotensin-converting enzyme inhibitors OR angiotensin receptor blockers OR ACEI OR ARB'. Additionally, a manual search of the retrieved articles, related review articles, and meta-analyses was conducted to identify other relevant articles.

2.2. Inclusion criteria {#sec0020}
-----------------------

Observational studies that met all the following criteria were included: (1) study design: case-control, case-crossover, self-controlled case series (SCCS) or cohort study; (2) antihypertensive treatment: ACEI/ARB use *versus* non-ACEI/ARB use; (3) outcomes: the incidence of COVID-19, critical cases, or death; (4) adequate data were used to extract the risk estimates if the adjusted data were not provided in the publication. Editorials, correspondences, conference abstracts and commentary articles were excluded in our study. When information was incomplete in the publication, attempts were made to contact the study investigators to obtain missing information.

2.3. Data extraction and quality assessment {#sec0025}
-------------------------------------------

Two investigators independently extracted all data from publications in a double-blinded manner. Any disagreements were resolved by a third investigator. The following information was extracted: name of first author, publication year, research type, study location, age, gender, number of participants, confounder adjustments, and study quality. If more than one estimate of effect was provided, the most-adjusted estimate was used for analysis. The Newcastle Ottawa Scale (NOS) was used to evaluate the methodological quality of the included publications \[[@bib0070]\]. The NOS features eight criteria and yields scores ranging from 0 (high risk of bias) to 9 (low risk of bias). Studies with NOS scores of \>7 were regarded as high quality.

2.4. Data synthesis and analysis {#sec0030}
--------------------------------

All meta-analytical calculations were performed with STATA software (version 14.0, Stata Corp LP, College Station, Texas). To provide a quantitative estimate of the association between ACEI/ARB use and severity or mortality risk in COVID-19 patients, the odds ratios (ORs) (most adjusted, if available) and the corresponding 95 % CIs were extracted from published articles. When the ORs were not given, tabular data were used to calculate the corresponding OR. Statistical heterogeneity of the included studies was calculated by using the χ^2^ test and the I^2^ statistic. An I^2^ \>50 % or a P \< 0.05 for the Q-statistic indicated substantial heterogeneity \[[@bib0075]\]. A random-effects model of the DerSimonian-Laird model was used to compare variance between studies \[[@bib0080]\]. Egger's regression test was employed to evaluate the publication bias \[[@bib0085]\]. Publication bias was not formally assessed because each meta-analysis included fewer than 10 studies. A P \< 0.05 was considered statistically significant \[[@bib0090]\].

3. Results {#sec0035}
==========

3.1. Search results {#sec0040}
-------------------

The search strategy identified 535 studies, of which 232 articles were duplicates. A total of 251 articles were excluded after reading the title and abstract. The remaining 53 articles were evaluated for this meta-analysis. One of the articles \[[@bib0095]\] was published as a poster in our hospital and the author was contacted for additional information. In total, 12 articles \[[@bib0095], [@bib0100], [@bib0105], [@bib0110], [@bib0115], [@bib0120], [@bib0125], [@bib0130], [@bib0135], [@bib0140], [@bib0145], [@bib0150]\] were eligible for this meta-analysis. The twelve articles of seven cohort studies and five case-control studies. Together, the included articles evaluated more than 19,000 COVID-19 patients . The list of excluded studies and the reasons for exclusion are listed in [Fig. 1](#fig0005){ref-type="fig"} .Fig. 1Flow chart showing the meta-analysis studies selection.Fig. 1

3.2. Patient characteristics {#sec0045}
----------------------------

The patient characteristics of the included studies are shown in [Table 1](#tbl0005){ref-type="table"} . Four studies \[[@bib0110],[@bib0130],[@bib0140],[@bib0150]\] were performed in Italy and USA, and one study \[[@bib0145]\] included the data from 11 countries in Asia, Europe, and North America. All other studies \[[@bib0095], [@bib0100], [@bib0105],[@bib0115], [@bib0120], [@bib0125],[@bib0135]\] came from China, mainly in Wuhan. All of the selected studies were published in 2020 with different sample patient sizes that ranged from 42 to 8910 patients. The overall average age of the subjects was greater than 60 years. Clinical outcomes were defined as COVID-19 infection in three studies, severity in severn studies, and mortality in eight studies. The results of the quality assessment of the included studies are presented in Supplementary Table S1 and S2.Table 1Characteristics of the Included Studies.Table 1AuthorCountry (city)Study designStudy periodAgeMaleMeasurement of ACEI/ARB useACEI/ARB\*Non- ACEI/ARB\*OutcomeConfounder adjustmentQualityFeng et al 2020China (Wuhan, Shanghai, Anhui)Multi-center retrospective case-controlJan 1 to Feb 15 202053 (40−64)57 %Medical record review3380SeverityNo5Li Juyi et al 2020China (Wuhan)Retrospective, single-center case seriesJan 15 to Mar 15 202066 (59−73)52 %Medical record review115247Severity and mortalityNo4Mancia et al 2020Italy (Lombardy region)Population-based case-controlFeb 21 to Mar 11 202068 ± 13NADatabases of health care useACEI 1502 ARB 1394NAInfection and SeverityNo9Meng et al 2020China (Shenzheng)Single-center retrospective cohortJan 11 to Feb 23 202064 (56−69)57 %Medical record review1725Severity and mortalityNo4Reynolds et al 2020USA (New York)Population-based cohortMar 1 to Apr 15 202064 (54--75)50 %Pharmacy fill records1091986Infection and MortalityNo9Tedeschi et al 2020Italy (Bologna)Prospective cohortFeb 1 to Apr 4 202076 (67−83)72 %Medical record review165136MortalityAge, gender, presence of CV comorbidities and COPD8Yang et al 2020China (Wuhan)Single-center retrospective cohortJan 5 to Feb 22 202066 (57−75)49 %Medical record review4383Severity and mortalityNo5Zhang et al 2020China (Wuhan)Retrospective, multi-center cohort studyDec 31 2019 to Feb 20 202064 (55−69)53 %Medical record review188940MortalityAge, gender, comorbidities and in-hospital medications9Mehra et al 2020Asia, Europe, and North AmericaRetrospective, multi-center study case-controlDec 20 2019 to Mar 12 202049 ± 1660%Medical record reviewACEI 770 ARB 556non-ACEI 8140 non-ARB 8354MortalityAge, race, coexisting conditions and medications8Yu et al 2020China (Zhejiang and Jiangsu)Retrospective, multi-center cohort studyJan 17 to Feb 19 202060 (52−68)53 %Medical record review103173MortalitySex, age, smoking, symptom, diabetes, cardiovascular diseases, chronic liver disease, and other comorbidity9Mehta et alUSA (Ohio and Florida)Retrospective cohortMar 8 to Apr 12 202049 ± 2140%Electronic medical recordsACEI 116 ARB 98non-ACEI 1619 non-ARB 1637Infection and MortalityPS matched9Li xiaochen et alChina (Wuhan)Retrospective case-controlJan 26 to Feb 5 202060 (48−69)50.90 %Medical record review42503SeverityNo4[^2]

3.3. Meta-analysis {#sec0050}
------------------

### 3.3.1. ACEI/ARB use and risk of COVID-19 infection {#sec0055}

Three studies reported the susceptibility to COVID-19 infection in patients on ACEI/ARB treatment. The combined OR of COVID-19 infection risk was 0.99 (95 % CI, 0.95--1.04), and no heterogeneity was observed among the studies (I^2^ = 0%, P = 0.504; [Table 2](#tbl0010){ref-type="table"} ). When the studies were grouped by drug type, the risk of COVID-19 infection was not significantly increased among individuals exposed to ACEI (OR = 0.98, 95 %CI, 0.92--1.04) or ARB (OR = 1.01, 95 % CI, 0.95--1.07, P = 0.044).Table 2Meta-analysis for studies included in the analysis.Table 2OutcomesNumber of studiesNumber of estimatesPooled OR (95 % CI), I^2^ statistics (%), P-value for the heterogeneity Q testModel used*COVID-19 infection*340.99 (0.95--1.04); I^2^ = 0%, P = 0.504Random effects ACEI330.98 (0.92--1.04); I^2^ = 0%, P = 0.542Random effects ARB331.01 (0.95--1.07); I^2^ = 8.9%, P = 0.334Random effects*COVID-19 Mortality*890.73 (0.5--1.07); I^2^ = 70.7%, P = 0.11Random effectsType of dataRandom effects Unadjusted440.91 (0.51--1.61); I^2^ = 33.4%, P = 0.212Random effects Adjusted450.66 (0.38--1.12); I^2^ = 82.2%, P \< 0.001Random effectsStudy locationRandom effects China550.65 (0.46−0.91); I^2^ = 0%, P = 0.529Random effects Other countries340.88 (0.48--1.62); I^2^ = 86.1%, P \< 0.001Random effects Patient with indication670.62 (0.38--1.02); I^2^ = 74.8%, P = 0.001Random effectsACEI/ARB *vs* non-ACEI/ARB antihypertensive drug440.48 (0.29−0.81); I^2^ = 0%, P = 0.3796Random effects*COVID-19 Severity*780.98 (0.87--1.09); I^2^ = 42.8%, P = 0.093Random effects Patient with indication560.95 (0.83--1.1); I^2^ = 57.6%, P = 0.038Random effects

### 3.3.2. ACEI/ARB use and risk of mortality in COVID-19 patients {#sec0060}

The overall analysis included nine studies. Together, 1631 COVID-19 cases with ACEI/ARB exposure and 11620 COVID-19 cases without ACEI/ARB esposure were included. The risk associated with ACEI/ARB use and increased mortalitywas estimated. Overall, the risk of mortality in ACEI/ARB-exposed was similar to non-ACEI/ARB exposed COVID-19 patients (OR = 0.73, 95 % CI, 0.5--1.07, P = 0.11). However, the studies had high (I^2^ = 70.7 %; P = 0.001; [Fig. 2](#fig0010){ref-type="fig"} ). A subgroup analyses of the data that included estimates showed that there was no significant increase in the mortality risk of patients with ACEI/ARB exposure regardless of unadjusted (OR = 0.66, 95 % CI, 0.38--1.12, P = 0.121) or adjusted estimates (OR = 0.91, 95 % CI, 0.51--1.61, P = 0.87). When studies were grouped by study location, there was a significantly lower mortality risk in studies from China (OR = 0.65, 95 % CI, 0.46−0.91, P = 0.013). There were no significant increase in mortality risk in studies form other countries (OR = 0.88, 95 % CI, 0.48--1.62, P = 0.689).Fig. 2Forest plot of ACEI/ARB exposure and risk of mortality in COVID-19 patients.Fig. 2

When our analysis was limited to the studies that only included patients on ACEI/ARBs for antihypertensive indications, a significantly lower risk of mortality was observed among those who used ACEI/ARB (OR = 0.62, 95 % CI, 0.38--1.02, P = 0.059; [Fig. 3](#fig0015){ref-type="fig"} ). After excluding studies that enrolled patients with hypertension not on antihypertensive treatment, a meta-analysis of four studies also found that ACEI/ARB exposure was associated with a lower risk of mortality compared to those on non-ACEI/ARB antihypertensive drugs (OR = 0.48, 95 % CI, 0.29−0.81, P = 0.006; I^2^ = 0%).Fig. 3Forest plot of ACEI/ARB exposure and risk of mortality in COVID-19 patients with antihypertensive indication.Fig. 3

### 3.3.3. ACEI/ARB use and influence on COVID-19 severity {#sec0065}

Seven studies that included 3070 COVID-19 cases with ACEI/ARB exposure and 3830 COVID-19 cases unexposed to ACEI/ARB reported on COVID-19 severity in relation to ACEI/ARB exposure. The combined OR of COVID-19 severity was 0.98 (95 % CI, 0.87--1.09, P = 0.69; [Fig. 4](#fig0020){ref-type="fig"} ). Moderate heterogeneity was observed among the studies (I^2^ = 42.8 %; P = 0.093). When our analysis was limited to the studies that only included patients on ACEI/ARB for antihypertensive indications, ACEI/ARB use was not associated with a higher risk of COVID-19 severity (OR = 0.95, 95 % CI, 0.83--1.1, P = 0.521; I^2^ = 57.6 %).Fig. 4Forest plot of ACEI/ARB exposure and risk of severity of COVID-19.Fig. 4

4. Discussion {#sec0070}
=============

This review included 12 articles that encompassed more than 19,000 COVID-19 cases. The findings suggest that ACEI/ARB use did not increase the risk of a positive COVID-19 test, or increase the risk of more severe infections, and did not increase mortality risk among patients with COVID-19. However, patient exposure to ACEI/ARBs for the trestment of hypertension was associated with a lower risk of mortality. This has potentially important implications in clinical practice.

Several systematic reviews \[[@bib0030],[@bib0155],[@bib0160]\] have demonstrated that individuals with underlying illness such as hypertension and CVD are susceptible to COVID-19 infection. However, ACEI/ARB treatment is widely used among these patients. This raises concerns about potential advantages or disadvantages of ACEI/ARB use COVID-19 infection\[[@bib0165]\]. SARS-CoV-2 binds to the extracellular domain of the transmembrane ACE2 receptor to entry host cells \[[@bib0045]\]. While ACEI and ARB have been shown to upregulate ACE2 expression in animal studies \[[@bib0035],[@bib0040]\], it is reasonable to hypothesize that hypertensive patients taking these drugs may have a higher risk of COVID-19 infection. Contrary to this hypothesis, our analysis did not provide evidence that patients should stop or substitute the ACEI or ARB medications previously prescribed. This may be result for two reasons. First, the effects of ACEI/ARB on the level of human plasma ACE2 are inconsistent \[[@bib0170]\]Second, none of the studies evaluated the effects of ACEI/ARBs on lung-specific expression of ACE2 \[[@bib0175]\]. To be relevant in SARS-CoV-2 infection, the effects on ACE2 would need to be present on respiratory epithelium. Second, beta blockers are identified as preventing ACE2 activity \[[@bib0180]\], which could underestimate the risk of COVID-19 associated ACEI/ARBs.

Another important issue is the use of ACEI/ARBs on the clinical outcomes of COVID-19 patients. Upon binding to ACE2, SARS-CoV subsequently reduces ACE2 expression in host cells. This results in activation of RAS, which in turn causes severe acute lung injury and exacerbates the progression of pneumonia \[[@bib0055]\]. According to this theory, a RAS inhibitor may improve the clinical outcomes of patients with COVID-19. In our overall analysis, ACEI/ARB exposure was not associated with a lower risk of COVID-19 severity or mortality. This may be explained by the drug indication. The latest systematic review \[[@bib0030]\] identified that COVID-19 patients with hypertension and CVD faced a greater risk of progressing to more critical or mortal illness. Several studies \[[@bib0100],[@bib0110],[@bib0125],[@bib0150]\] included patients without hypertension and CVD in the non-ACEI/ARB group, which may underestimate the protective effect of ACEI/ARB use in COVID-19 patients. Further analysis of studies that only included patients using an ACEI/ARB indicated for hypertension found that patients on ACEI/ARBs had a lower risk of mortality. This finding is further reinforced by the relatively lower but significant risk observed in patients with hypertension.

To our knowledge, this systematic review and meta-analysis is the first to evaluate the role of ACEI/ARBs as an antihypertensive regimen in patients with COVID-19. The key strength of our meta-analysis lies in its large sample size and comprehensive search. The accumulating evidence and large sample size enhanced the statistical power of this study to provide more precise and reliable risk estimates. In the included studies, more than 19,000 COVID cases were included in the analysis of severity and mortality. Furthermore, we conducted additional analyses to control for confounding factors by indication.

Nonetheless, this review has some major limitations. The most important limitation of our meta-analysis is the residual number of unknown confounders. Previous studies have reported that sex, age, smoking, and diabetes greatly affect the prognosis of COVID-19 infection. However, these potential confounders are considered in most of the included studies. Future research should report analyses stratified by possible risk factors that fully adjust for potential confounders to rule out alternative explanations. Another limitation is that there was only a small number of eligible high-quality studies was small, which may have influenced the accuracy of the results. Third, the measurement of ACEI/ARB exposure was through medical record review, which is less reliable than other methods. This may have influenced the findings. Fourth, although only mild heterogeneity was observed in the analysis of COVID-19 severity, the existence of clinical heterogeneity is expected to lead to a degree of statistical heterogeneity in the results. The definitions of COVID-19 severity and outcomes were inconsistent among the included studies. Finally, the results of this review are susceptible to selection bias given that most of the patients in the study population were in a hospital.

In conclusion, the results of the meta-analysis suggest that use of ACEI/ARB in patients with COVID-19 does not increase the risk of COVID-19 infection, severity, or mortality. However, a lower risk of mortality was observed among those patients who were taking ACEI/ARB for the treatment of hypertension. The findings suggest that ACEI/ARB treatment should be continued in COVID-19 patients who are taking these medications for antihypertensive treatment.

Authors' contributions {#sec0075}
======================

H.Y.J. and Z.X. conceived the study and revised the manuscript critically for important intellectual content. Z.X., and J.Y. made substantial contributions to its design, acquisition, analysis and interpretation of data. L.Y.P. participated in the design, acquisition, analysis and interpretation of data. All authors read and approved the final manuscript.

Funding {#sec0080}
=======

This study was supported by Zhejiang Provincial Natural Science Foundation of China (Grant No. LY20H090012).

Declaration of Competing Interest
=================================

The authors declare that they have no competing interest. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Appendix A. Supplementary data {#sec0090}
==============================

The following is Supplementary data to this article:
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